Interleukin-1 (IL-1) Inhibitors (e.g., Anakinra, Canakinumab)

Type: drug

Status: FDA Approved (for sJIA, used off-label for AOSD)

Developer: Sobi (Anakinra), Novartis (Canakinumab)

Breakthrough Summary

No summary available.

Mechanism of Action

Details pending.

Year: 2026